EGFR and colorectal cancer: In BRAF mutant colorectal cancers, EGFR-mediated adaptive resistance severely limits the response to single-agent BRAF inhibition as well as combined BRAF and MEK inhibition; however, increased response rates to the triple combination of BRAF (dabrafenib), EGFR (panitumumab), and MEK inhibition (trametinib) have been observed in the clinic [105].